Add to ORKGThere is some evidence that dextromethorphan (DM) is effective as a preemptive analgesic agent. DM is mainly metabolized to dextrorphan (DOR) by CYP2D6 whose activity can be inhibited by pharmacologic intervention
<p>A single dose of the CYP2D6 inhibitor quinidine (30 mg/kg, i.p.) administered concomitantly with ...
AbstractThe symptoms of neuropathic pain are often intractable because they are poorly relieved by c...
Dextromethorphan (DM) is O-demethylated to its main metabolite, dextrorphan (DO), following a polymo...
BACKGROUND: There is some evidence that dextromethorphan (DM) is effective as a pre-emptive analgesi...
Dextromethorphan (DEM)-mediated N-methyl-D-aspartate receptor blockade may result from an action of ...
Administration of NMDA antagonists leads to attenuation or disappearance of some symptoms of central...
Experimental studies have indicated that N-methyl-D-aspartate (NMDA) receptor antagonists may be eff...
AbstractDextromethorphan (DM) has been used for more than 50years as an over-the-counter antitussive...
ObjectivesWe studied the disposition of dextromethorphan in extensive and poor metabolizer subjects,...
The pharmacokinetics of dextromethorphan (DM) is markedly influenced by cytochrome P450 2D6 (CYP2D6)...
Conclusion. Peroral administration of dextromethorphan (0,6 mg/kg) is sufficient to block the centra...
This study provides a whole-body physiologically-based pharmacokinetic (PBPK) model of dextromethorp...
We report a case of life-threatening intoxication and a controlled re-exposure study to dextromethor...
Dextromethorphan (DM) has been used for more than 50 years as an over-the-counter antitussive. Studi...
BACKGROUND Dextromethorphan (DEX) is an NMDA receptor antagonist which has recently been introduced ...
<p>A single dose of the CYP2D6 inhibitor quinidine (30 mg/kg, i.p.) administered concomitantly with ...
AbstractThe symptoms of neuropathic pain are often intractable because they are poorly relieved by c...
Dextromethorphan (DM) is O-demethylated to its main metabolite, dextrorphan (DO), following a polymo...
BACKGROUND: There is some evidence that dextromethorphan (DM) is effective as a pre-emptive analgesi...
Dextromethorphan (DEM)-mediated N-methyl-D-aspartate receptor blockade may result from an action of ...
Administration of NMDA antagonists leads to attenuation or disappearance of some symptoms of central...
Experimental studies have indicated that N-methyl-D-aspartate (NMDA) receptor antagonists may be eff...
AbstractDextromethorphan (DM) has been used for more than 50years as an over-the-counter antitussive...
ObjectivesWe studied the disposition of dextromethorphan in extensive and poor metabolizer subjects,...
The pharmacokinetics of dextromethorphan (DM) is markedly influenced by cytochrome P450 2D6 (CYP2D6)...
Conclusion. Peroral administration of dextromethorphan (0,6 mg/kg) is sufficient to block the centra...
This study provides a whole-body physiologically-based pharmacokinetic (PBPK) model of dextromethorp...
We report a case of life-threatening intoxication and a controlled re-exposure study to dextromethor...
Dextromethorphan (DM) has been used for more than 50 years as an over-the-counter antitussive. Studi...
BACKGROUND Dextromethorphan (DEX) is an NMDA receptor antagonist which has recently been introduced ...
<p>A single dose of the CYP2D6 inhibitor quinidine (30 mg/kg, i.p.) administered concomitantly with ...
AbstractThe symptoms of neuropathic pain are often intractable because they are poorly relieved by c...
Dextromethorphan (DM) is O-demethylated to its main metabolite, dextrorphan (DO), following a polymo...